Please login to the form below

Not currently logged in
Email:
Password:

Kisqali

This page shows the latest Kisqali news and features for those working in and with pharma, biotech and healthcare.

FDA backs earlier use of Lilly’s breast cancer drug Verzenio

FDA backs earlier use of Lilly’s breast cancer drug Verzenio

year and is predicted to become a $6bn product at peak by EvaluatePharma - as well as Novartis’second-to-market CDK4/6 inhibitor Kisqali (ribociclib)). ... Kisqali made $35m in its first few months on the market after launches in the US and Europe in

Latest news

More from news
Approximately 6 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is a creative agency specialising in healthcare communication and understanding people's personality types....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics